1 |
Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, et al. Management of posttransplant lymphopro!iferative disease in pediatric liver transplant recipients receiving primary tacrolimus(FK506) therapy. Transplantation 1998;66:1047-52
DOI
ScienceOn
|
2 |
Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003;18(suppl 1): i12-i15
DOI
ScienceOn
|
3 |
Sanchez CP, Salusky I, Kuizou B, Ramirez JA, Gates B, Ettenger RB, et al. Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 1998;53:1358-64
DOI
ScienceOn
|
4 |
Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996;348:643-8
DOI
ScienceOn
|
5 |
Chakrabarti P, Wong HY, Scantlebury VP, Jordan ML, Vivas C, Ellis D, et al. Outcome after steroid withdrawal in pediatric renal transplantation patients receiving tacrolimusbased immunosuppression. Transplantation 2000;70:760-4
DOI
ScienceOn
|
6 |
Filler G, Grygas R, Mai I, Stolpe HJ, Greiner C, Bauer S, et al. Pharmacokinetic of tacrolirnus(FK-506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997;12:1668-71
DOI
ScienceOn
|
7 |
Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomized trials. BMJ 1999;318:1104-7
DOI
ScienceOn
|
8 |
Del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for pediatric transplant patients: Pharmacokinetic considerations. Clin Pharmacokinet 2002:41:115-35.
DOI
ScienceOn
|
9 |
Filler G, Feber J. Lepage N, Weiler G, Mai I. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 2002;6:411-8
DOI
ScienceOn
|
10 |
Webb NJA, Stevenson PJ, Lewis MA, Postiethwaite RJ, Bradbury MG, Undre NA. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 2002;34:1948-1950
DOI
ScienceOn
|
11 |
Sarwal MM, Vidhun J, Alexander SR, Satterwhite T, MilIan M, Salvatierra O Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003;76:1331-9
DOI
ScienceOn
|
12 |
Maiorca R, Cristinelli L, Brunori G, Setti G, Salemi B, De Nobili U, et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporin. Transplant Proc 1988;20(suppl 3):121-5
|
13 |
Cooney GF, Habucky K, Hoppu K. Cyclosporine pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet 1997;32:481-95
DOI
ScienceOn
|
14 |
Feld LG, Stablein D, Fivush B, Harmon W, Tejani A. Renal transplantation in children from 1987-1996: The 1996 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 1997;1:146-62
|
15 |
Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996;10:118-23
|
16 |
NARPTCS. 2002 Annual Report of the North American Pediatric Renal Transplant Cooperative Study(NAPRTCS). 2002, Section 3
|
17 |
Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993:46:746-94
DOI
ScienceOn
|
18 |
Hoyer PF. Cvclosporin A(Neorai) in pediatric organ transplantation. Pediatr Transplant 1998;2:35-9
|
19 |
Shishido S, Asanuma H, Tajima E, Honda M, Nakai H. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 2001;33:1066-8
DOI
ScienceOn
|
20 |
Barama A. Sepandj F, Gough J. Mckenna R. Correlation between neoral 2 hours post-dose levels and histologic findings on surveillance biopsies. Transplant Proc 2004;36(2 suppl):465S-467S
|
21 |
Keown P, Kahan BD, Johnston A, Levy G, Dunn SP, Cittero F, et al. Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the international Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). Transplant Proc 1998;30: 1645-9
DOI
|
22 |
Johnston A, David OJ, Cooney GF. Pharmacokinetic validation of neoral absorption profiling. Transplant Proc 2000;2 (suppl 3A):53S-56S
|
23 |
Shaw LM, Holt DW, Keown P, Venkataramanan R, Yatscoff RW. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999;21:1632-52
DOI
ScienceOn
|
24 |
Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002;72:660-9
DOI
ScienceOn
|
25 |
Tonshoff B, Mehls O. Factors affecting growth and strategies for treatment in children after renal transplantation. Pediatr Transplant 1997;1 :176-82
|
26 |
Ellis D, Shapiro R, Jordan ML, Scantlebury VP, Gilboa N, Hopp L, et al. Comparison of FK -506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol 1994;8:193-200
DOI
ScienceOn
|
27 |
Kim JS, Aviles DH, Silverstein DM, LeBlanc PL, Vehas kari VM. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005(in press)
|
28 |
Hoyer PF, Boekenkamp A, Vester U, Offner G, Brodehl J. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients. Transplant Proc 1996;28:2259-61
|
29 |
Dunn TB, Asolati M, Holman DM, Raofi V, Jovanovic B, Pollak R, et al. Long-term outcomes of a prospective trial of steroid withdrawal after kidney transplantation. Surgery 1999;125:155-9
DOI
ScienceOn
|
30 |
Belitsky P, Levy GA, Johnston A, Levy G. Impact of absorption profiling on efficacy and safety of cyclosporine therapy in transplant recipients. Clin Pharmacokinet 2000; 39:117-25
DOI
ScienceOn
|